Positive Study Results, Acquisitions, Drug Approval, Regulatory Updates, and Collaborations - Research Reports on Gilead, Pfizer, AbbVie, Pacira and Thermo Fisher

NEW YORK, September 30, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Gilead Sciences Inc. (NASDAQ: GILD), Pfizer Inc. (NYSE: PFE), AbbVie Inc. (NYSE: ABBV), Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) and Thermo Fisher Scientific, Inc. (NYSE: TMO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6854-100free.

--
Gilead Sciences Inc. Research Reports
On September 24, 2014, Gilead Sciences Inc. (Gilead) announced that two Phase III clinical trials evaluating an investigational tablet regimen containing tenofovir alafenamide (TAF) for the treatment of HIV-1 infection in treatment-naïve adults met their primary objectives. According to the Company, the studies demonstrated that the single tablet regimen containing TAF was non-inferior to the Gilead's already approved HIV drug Stribild, based on the proportion of patients with HIV RNA levels (viral load) of less than 50 copies/ mL at 48 weeks of therapy. In addition, the drug containing TAF demonstrated more favorable renal and bone safety compared to Stribild. Gilead plans to submit regulatory applications for TAF in the U.S. and EU in Q4 2014. The full research reports on Gilead are available to download free of charge at:

http://www.analystsreview.com/Sep-30-2014/GILD/report.pdf

--
Pfizer Inc. Research Reports
On September 25, 2014, Pfizer Inc. (Pfizer) announced that it has completed its acquisition of the pharmaceutical development company, InnoPharma, Inc., after receiving regulatory approvals from all the U.S. government authorities as required by the agreement. Commenting on the acquisition, John Young, Group President, Pfizer Global Established Pharma (GEP), said "We believe this acquisition will help Pfizer build a strong sterile injectables pipeline in areas such as oncology and central nervous disorders." The full research reports on Pfizer are available to download free of charge at:

http://www.analystsreview.com/Sep-30-2014/PFE/report.pdf

--
AbbVie Inc. Research Reports
On September 25, 2014, AbbVie Inc. (AbbVie) announced that the U.S. Food and Drug Administration (FDA) has approved HUMIRA (adalimumab) for the treatment of pediatric patients 6 years of age or older with moderately to severely active Crohn's disease, when certain other treatments have not worked well enough. According to the Company, Humira also becomes the first biologic approved drug in the U.S. that can be administered at home. "Children living with moderate to severe Crohn's disease have limited treatment options and AbbVie is pleased that HUMIRA will now be an available option for many of these patients," said Michael Severino, M.D., Executive Vice President, Research and Development and Chief Scientific Officer, AbbVie. The full research reports on AbbVie are available to download free of charge at:

http://www.analystsreview.com/Sep-30-2014/ABBV/report.pdf

--
Pacira Pharmaceuticals, Inc. Research Reports
On September 25, 2014, Pacira Pharmaceuticals, Inc. (Pacira) announced that it has received a warning letter from the U.S. Food and Drug Administration's (FDA) Office of Prescription Drug Promotion (OPDP) regarding the promotional materials on the Company's EXPAREL (bupivacaine liposome injectable suspension). In its letter to the Company, the OPDP has said that it has evidence that Exparel is intended for new uses for which it does not have approval, and for which its labeling does not provide adequate directions for use, which renders Exparel "misbranded". OPDP also said that the Company has promoted its Exparel as being able to control the pain beyond 24 hours when this has not been demonstrated. "These claims overstate Exparel's efficacy and are misleading," said OPDP in its letter. In response to the letter, Placira's Chairman, President and CEO Dave Stack stated, "We plan to explain our position to the FDA and will provide an update upon resolution of these issues." Shares of Pacira fell 10.97% to close at $94.62. The full research reports on Pacira are available to download free of charge at:

http://www.analystsreview.com/Sep-30-2014/PCRX/report.pdf

--
Thermo Fisher Scientific, Inc. Research Reports
On September 25, 2014, Thermo Fisher Scientific, Inc. (Thermo Fisher) announced a collaboration with GlaxoSmithKline and Pfizer to develop a universal next-generation sequencing (NGS) oncology test for solid tumors that will serve as a companion diagnostic for multiple drug programs. The test will be developed using Thermo Fisher's Ion Personal Genome Machine (PGM) Dx Platform, Ion AmpliSeq technology, and content from the Oncomine Cancer Research Panel. Once developed and validated, the test will be submitted to the U.S. Food and Drug Administration (FDA) and other global regulatory authorities for premarket approval, said Thermo Fisher. "This collaboration with Pfizer and GSK enables us to build upon our market leading position in NGS oncology, with hundreds of customers around the world sequencing tens of thousands of tumor samples each month using Ion Torrent technology," said Mark Stevenson, President of Life Sciences Solutions at Thermo Fisher. The full research reports on Thermo Fisher are available to download free of charge at:

http://www.analystsreview.com/Sep-30-2014/TMO/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review